Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 2/20 | 0.39 |
| ▸ | SPR | P35270 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551867 | 0.89 | NOTUM (0.45) | JAK2JAK1TYK2NOTUM | |
| SCHEMBL22637662 | 0.84 | IRAK4 (0.46) | JAK2JAK1TYK2SPRLRRK2 | |
| SCHEMBL23289669 | 0.82 | JAK2 (0.42) | JAK2JAK1TYK2CFTRIRAK4 | |
| SCHEMBL20552487 | 0.78 | TGFBR1 (0.39) | JAK2JAK1TYK2 | |
| SCHEMBL18012432 | 0.77 | LRRK2 (0.43) | JAK2JAK1TYK2LRRK2IRAK4 | |
| SCHEMBL17619401 | 0.76 | KDM4C (0.53) | LRRK2IRAK4 | |
| SCHEMBL26029500 | 0.76 | MGLL (0.39) | JAK2JAK1TYK2LRRK2NOTUM | |
| SCHEMBL5122723 | 0.75 | ABL1 (0.38) | NOTUM | |
| SCHEMBL5021087 | 0.74 | LRRK2 (0.41) | JAK2JAK1TYK2LRRK2IRAK4 | |
| SCHEMBL25067443 | 0.74 | LRRK2 (0.41) | JAK2JAK1TYK2LRRK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | JAK2 4092/4885JAK1 4250/4885TYK2 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.